Long-acting injectable antipsychotics: An underutilized treatment option. Interim results of an e-STAR trial with injectable risperidone in the Czech and Slovak Republics
2008
Abstract
The long-acting injectable antipsychotics increase medication adherence to maintenance therapy of schizophrenia. Although effective in preventing relapses and reducing rehospitalizations, these drugs are an underutilized treatment option.
The advantages and drawbacks of depot antipsychotics and some myths abouts this therapy are reviewed as well as pharmacological characteristics of long-acting risperidone, so far the only long-acting second-generation antipsychotic in clinical use. The e-STAR (Electronic Schizophrenia Treatment Adherence Registry) study and its interim results obtained in the Czech and Slovak Republics are briefly presented.